{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033743","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.743875+00:00","generated_at":"2026-05-31T14:18:34.660002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vanda Q2 2024 revenue $50.5M (+10% YoY); net loss $4.5M; Fanapt bipolar launch underway","bullets":["Q2 2024 total revenues $50.5M (up 10% YoY); net loss $4.5M vs net income $1.5M in Q2 2023.","Fanapt approved for bipolar I disorder; commercial launch initiated in Q3 2024; PONVORY launch for MS also started.","Tradipitant NDA for gastroparesis under FDA review; PDUFA date Sept 18, 2024; FDA preliminary notice of deficiencies.","HETLIOZ net sales $18.7M (-15% YoY) amid generic competition; lawsuit vs Teva/Apotex allowed to proceed.","Full-year 2024 guidance: total revenues $180-210M; year-end cash $360-390M; cash $387.7M at June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033743","json":"https://secwatch.observer/filing/0001628280-24-033743.json","markdown":"https://secwatch.observer/filing/0001628280-24-033743.md","text":"https://secwatch.observer/filing/0001628280-24-033743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/0001628280-24-033743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828024033743/vnda-20240731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:18:34.660002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}